Chemopreventive actions by enterolactone and 13 VIOXX-related lactone derivatives in H295R human adrenocortical carcinoma cells

Toxicol Lett. 2010 Feb 15;192(3):271-7. doi: 10.1016/j.toxlet.2009.11.001. Epub 2009 Nov 11.

Abstract

Cytochrome P450c17 (CYP17) has been linked to various hormone-related diseases, including breast cancer, thus being a potential target for cancer chemoprevention. We studied the naturally occurring phytochemical enterolactone (ENL) and 13 VIOXX-related lactone derivatives (CRI-1 to CRI-13) for their effects on CYP17 activity and expression and on cell cycle status in the human H295R adrenocorticocarcinoma cell line. Of the tested compounds, only CRI-3, -7, -10 and -12 showed to be inhibitors of CYP17 activity in H295R cells. This inhibition was not due to decreased mRNA expression, but was apparently caused by post-translational modification of the CYP17 enzyme. The MAPK kinase (MEK) inhibitor PD98059 induced CYP17 activity by 24%, while co-incubation of the CRI-s with PD98059, reduced CYP17 activity even further than the reduction caused by the CRI-s alone. In addition, CRI-3, -7, -10 and -12 arrested the cell cycle in the G(2)/M phase. The structure-activity similarities of the CRI-s with known micro-tubule binding agents strongly suggest that cell cycle arrest is a result of interaction with tubulin. We conclude that the proposed cancer chemopreventive actions of ENL are not mediated through interaction with CYP17 or cell cycle status. Of the VIOXX-related lactone derivatives, CRI-7 could prove useful in the prevention of hormone-dependent cancers, such as breast cancer, since in vitro it shows low cytotoxicity, it is a potent inhibitor of CYP17 activity and strong inducer of cell cycle arrest.

MeSH terms

  • 4-Butyrolactone / analogs & derivatives*
  • 4-Butyrolactone / pharmacology
  • Adrenal Cortex Neoplasms / enzymology*
  • Adrenal Cortex Neoplasms / physiopathology
  • Adrenocortical Carcinoma / enzymology*
  • Adrenocortical Carcinoma / physiopathology
  • Cell Cycle / drug effects
  • Cell Line, Tumor
  • Enzyme Induction / drug effects
  • Flavonoids / pharmacology
  • Gene Expression / drug effects
  • Humans
  • Lactones / pharmacology*
  • Lignans / pharmacology*
  • Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors
  • Neoplasms, Hormone-Dependent / prevention & control
  • Phytoestrogens / pharmacology*
  • Protein Processing, Post-Translational / drug effects
  • Steroid 17-alpha-Hydroxylase / antagonists & inhibitors
  • Steroid 17-alpha-Hydroxylase / biosynthesis
  • Steroid 17-alpha-Hydroxylase / drug effects*
  • Structure-Activity Relationship
  • Sulfones / pharmacology*

Substances

  • Flavonoids
  • Lactones
  • Lignans
  • Phytoestrogens
  • Sulfones
  • rofecoxib
  • Steroid 17-alpha-Hydroxylase
  • Mitogen-Activated Protein Kinase Kinases
  • 4-Butyrolactone
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one
  • 2,3-bis(3'-hydroxybenzyl)butyrolactone